Treatment Choice and Outcomes for End Stage Renal Disease: Evidence from the First Year of a Nationwide Randomized Evaluation
How to cite
Finkelstein, Amy; Ji, Yunan; Mahoney, Neale; Einav, Liran. 2021. "Treatment Choice and Outcomes for End Stage Renal Disease: Evidence from the First Year of a Nationwide Randomized Evaluation." AEA RCT Registry. AEARCTR-0008034. https://doi.org/10.1257/rct.8034-2.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
We plan to analyze the first year of a nationwide randomized-controlled trial of end stage renal disease (ESRD) treatment choice. This mandatory-participation program was designed by the Centers for Medicare and Medicaid Services and randomization was conducted at the hospital referral region (HRR) level. 95 HRRs were assigned to the treatment group beginning in January 2021. We will study the impact of this program in the first year on treatment modality choice for ESRD and explore heterogeneity in impact across patients and providers.
Experimental design
We propose to study the ESRD Treatment Choice (ETC) program, a nationwide randomized-controlled trial (RCT) of ESRD treatment that was designed by the Centers for Medicare and Medicaid Services (CMS) to encourage greater use of home dialysis. The RCT creates payment adjustments for ESRD facilities and clinicians based on the rates of home dialysis and transplantation. The RCT was first announced in July 2019 for a start date of January 1, 2020 which was later delayed to January 1, 2021. In September 2020, 30% of hospital referral regions (HRRs) were assigned to treatment through a stratified randomization procedure. The RCT is scheduled to last until June 2027.
The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
Design details
Materials
Papers from this trial
- Ji Y, Einav L, Mahoney N, Finkelstein A. Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial. JAMA Health Forum. 2022;3(10):e223503. doi:10.1001/jamahealthforum.2022.3503 https://jamanetwork.com/journals/jama-health-forum/fullarticle/2797080
Cited by
No citation data available for this registration yet.